These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

458 related items for PubMed ID: 35603992

  • 1. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study.
    Megna M, Tommasino N, Potestio L, Battista T, Ruggiero A, Noto M, Fabbrocini G, Genco L.
    J Dermatolog Treat; 2022 Sep; 33(6):2813-2820. PubMed ID: 35603992
    [Abstract] [Full Text] [Related]

  • 2. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice.
    Ruggiero A, Fabbrocini G, Cinelli E, Ocampo Garza SS, Camela E, Megna M.
    Clin Exp Dermatol; 2022 Mar; 47(3):561-567. PubMed ID: 34642965
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.
    Torres T, Puig L, Vender R, Yeung J, Carrascosa JM, Piaserico S, Gisondi P, Lynde C, Ferreira P, Bastos PM, Dauden E, Leite L, Valerio J, Del Alcázar-Viladomiu E, Rull EV, Llamas-Velasco M, Pirro F, Messina F, Bruni M, Licata G, Ricceri F, Nidegger A, Hugo J, Mufti A, Daponte AI, Teixeira L, Balato A, Romanelli M, Prignano F, Gkalpakiotis S, Conrad C, Lazaridou E, Rompoti N, Papoutsaki M, Nogueira M, Chiricozzi A.
    Am J Clin Dermatol; 2022 Nov; 23(6):891-904. PubMed ID: 35976568
    [Abstract] [Full Text] [Related]

  • 5. Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis.
    Elgaard CDB, Iversen L, Hjuler KF.
    J Dermatolog Treat; 2023 Dec; 34(1):2133531. PubMed ID: 36200762
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS).
    Gargiulo L, Ibba L, Malagoli P, Angileri RG, Bardazzi F, Bernardini N, Burlando M, Carrera CG, Chiricozzi A, Dapavo P, Dini V, Fabbrocini G, Gaiani FM, Galluzzo M, Giofré C, Guarneri C, Loconsole F, Malara G, Marcelli L, Megna M, Piaserico S, Talamonti M, Costanzo A, Narcisi A.
    J Eur Acad Dermatol Venereol; 2023 May; 37(5):1017-1027. PubMed ID: 36695061
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Bai F, Li GG, Liu Q, Niu X, Li R, Ma H.
    J Immunol Res; 2019 May; 2019():2546161. PubMed ID: 31583255
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence.
    Ruggiero A, Picone V, Martora F, Fabbrocini G, Megna M.
    Clin Cosmet Investig Dermatol; 2022 May; 15():1649-1658. PubMed ID: 35996400
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of risankizumab in psoriasis patients who failed anti-IL-17, anti-12/23 and/or anti IL-23: Preliminary data of a real-life 16-week retrospective study.
    Megna M, Fabbrocini G, Ruggiero A, Cinelli E.
    Dermatol Ther; 2020 Nov; 33(6):e14144. PubMed ID: 32761740
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER - study).
    Orsini D, Caldarola G, Dattola A, Campione E, Bernardini N, Frascione P, De Simone C, Richetta AG, Galluzzo M, Skroza N, Assorgi C, Amore E, Falco GM, Gaeta Shumak R, Artosi F, Maretti G, Potenza C, Bianchi L, Pellacani G, Peris K, Bonifati C, Graceffa D.
    J Dermatolog Treat; 2024 Dec; 35(1):2319304. PubMed ID: 38413097
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.